Technology
Health
Biotechnology

VistaGen Therapeutics

$1.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.79%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VTGN and other stocks, options, ETFs, and crypto commission-free!

About

VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. Read More It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Employees
9
Headquarters
South San Francisco, California
Founded
1998
Market Cap
39.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
475.57K
High Today
$1.32
Low Today
$1.26
Open Price
$1.29
Volume
169.00K
52 Week High
$2.44
52 Week Low
$0.8101

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
US

News

Seeking AlphaMar 19

VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow

The following slide deck was published by VistaGen Therapeutics, Inc. in conjunction with this event. 1 36 Click to enlarge Notes:...

136
Yahoo FinanceFeb 27

Four Tech Stocks Looking To Test February Highs

CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / Nothing in life is guaranteed, but based on the first few months of the year, the future of the tech stock market looks to be in good shape.

391
MarketBeatFeb 20

Stock Price, News, & Analysis for Vistagen Therapeutics

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemica...

62

Earnings

-$0.53
-$0.38
-$0.24
-$0.09
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Jun 26, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.